The LncRNA 'UCA1' Modulates the Response to Chemotherapy of Ovarian Cancer Through Direct Binding to MiR-27a-5p and Control of UBE2N Levels

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2021 Jun 23

PMID 34160887

Citations 19

Authors

Anais Wambecke

Mohammad Ahmad

Pierre-Marie Morice

Bernard Lambert

Louis-Bastien Weiswald

Megane Vernon

Nicolas Vigneron

Edwige Abeilard

Emilie Brotin

Martin Figeac

Pascal Gauduchon

Laurent Poulain

Christophe Denoyelle

Matthieu Meryet-Figuiere

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is the leading cause of death in patients with gynecologic cancers. Due to late diagnosis and resistance to chemotherapy, the 5-year survival rate in patients with OC is below 40%. We observed that UCA1, a lncRNA previously reported to play an oncogenic role in several malignancies, is overexpressed in the chemoresistant OC cell line OAW42-R compared to their chemotherapy-sensitive counterpart OAW42. Additionally, UCA1 overexpression was related to poor prognosis in two independent patient cohorts. Currently, the molecular mechanisms through which UCA1 acts in OC are poorly understood. We demonstrated that downregulation of the short isoform of UCA1 sensitized OC cells to cisplatin and that UCA1 acted as competing endogenous RNA to miR-27a-5p. Upon UCA1 downregulation, miR-27a-5p downregulated its direct target UBE2N leading to the upregulation of BIM, a proapoptotic protein of the Bcl2 family. The upregulation of BIM is the event responsible for the sensitization of OC cells to cisplatin. In order to model response to therapy in patients with OC, we used several patient-derived organoid cultures, a model faithfully mimicking patient's response to therapy. Inhibition of UBE2N sensitized patient-derived organoids to platinum salts. In conclusion, response to treatment in patients with OC is regulated by the UCA1/miR-27a-5p/UBE2N axis, where UBE2N inhibition could potentially represent a novel therapeutic strategy to counter chemoresistance in OC.

Citing Articles

MiR-27a-5p inhibits malignant progression of differentiated thyroid cancer by directly affecting the miR-27a-5p/SREBP1 axis.

Xie Z, Liu J, Zhou J, Zhang X, Li Z J Endocrinol Invest. 2025; .

PMID: 39946050 DOI: 10.1007/s40618-025-02550-3.

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.

TAF15 inhibits p53 nucleus translocation and promotes HCC cell 5-FU resistance via post-transcriptional regulation of UBE2N.

Fang J, Zou M, Yang M, Cui Y, Pu R, Yang Y J Physiol Biochem. 2024; 80(4):919-933.

PMID: 39446246 DOI: 10.1007/s13105-024-01053-8.

Integrated miRNA Profiling of Extracellular Vesicles from Uterine Aspirates, Malignant Ascites and Primary-Cultured Ascites Cells for Ovarian Cancer Screening.

Skryabin G, Komelkov A, Zhordania K, Bagrov D, Enikeev A, Galetsky S Pharmaceutics. 2024; 16(7).

PMID: 39065600 PMC: 11280431. DOI: 10.3390/pharmaceutics16070902.

Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.

Thorel L, Perreard M, Florent R, Divoux J, Coffy S, Vincent A Exp Mol Med. 2024; 56(7):1531-1551.

PMID: 38945959 PMC: 11297165. DOI: 10.1038/s12276-024-01272-5.

References

Wang F, Ying H, He B, Pan Y, Deng Q, Sun H . Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015; 6(10):7899-917. PMC: 4480724. DOI: 10.18632/oncotarget.3219. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Lheureux S, Braunstein M, Oza A . Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019; 69(4):280-304. DOI: 10.3322/caac.21559. View

Wang B, Elledge S . Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci U S A. 2007; 104(52):20759-63. PMC: 2410075. DOI: 10.1073/pnas.0710061104. View

Zhang X, Gao F, Zhou L, Wang H, Shi G, Tan X . UCA1 Regulates the Growth and Metastasis of Pancreatic Cancer by Sponging miR-135a. Oncol Res. 2017; 25(9):1529-1541. PMC: 7841060. DOI: 10.3727/096504017X14888987683152. View

Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M . Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis. 2014; 5:e1008. PMC: 4040676. DOI: 10.1038/cddis.2013.541. View

Petigny-Lechartier C, Duboc C, Jebahi A, Louis M, Abeilard E, Denoyelle C . The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737. Mol Cancer Ther. 2016; 16(1):102-115. DOI: 10.1158/1535-7163.MCT-16-0342. View

Hodge C, Spyracopoulos L, Glover J . Ubc13: the Lys63 ubiquitin chain building machine. Oncotarget. 2016; 7(39):64471-64504. PMC: 5325457. DOI: 10.18632/oncotarget.10948. View

Ziegler C, Kretz M . The More the Merrier-Complexity in Long Non-Coding RNA Loci. Front Endocrinol (Lausanne). 2017; 8:90. PMC: 5403818. DOI: 10.3389/fendo.2017.00090. View

10.

Mizuno K, Mataki H, Arai T, Okato A, Kamikawaji K, Kumamoto T . The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes. J Hum Genet. 2017; 62(7):671-678. DOI: 10.1038/jhg.2017.27. View

11.

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

12.

Kondo J, Inoue M . Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Cells. 2019; 8(5). PMC: 6562517. DOI: 10.3390/cells8050470. View

13.

Coleman R . Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol. 2016; 13(2):71-2. DOI: 10.1038/nrclinonc.2015.225. View

14.

Villedieu M, Deslandes E, Duval M, Heron J, Gauduchon P, Poulain L . Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol. 2006; 101(3):507-19. DOI: 10.1016/j.ygyno.2005.11.017. View

15.

Xue M, Chen W, Li X . Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer. J Cancer Res Clin Oncol. 2015; 142(7):1407-19. DOI: 10.1007/s00432-015-2042-y. View

16.

Pujade-Lauraine E, Fujiwara K, Dychter S, Devgan G, Monk B . Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design. Future Oncol. 2018; 14(21):2103-2113. DOI: 10.2217/fon-2018-0070. View

17.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

18.

Fang Z, Zhao J, Xie W, Sun Q, Wang H, Qiao B . LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. Cancer Med. 2017; 6(12):2897-2908. PMC: 5727307. DOI: 10.1002/cam4.1253. View

19.

Lucas J, Hsieh T, Halicka H, Darzynkiewicz Z, Wu J . Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling. Int J Oncol. 2018; 53(4):1469-1480. PMC: 6086626. DOI: 10.3892/ijo.2018.4512. View

20.

Meryet-Figuiere M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L . An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016; 7(28):44719-44734. PMC: 5190131. DOI: 10.18632/oncotarget.8089. View